Extravan FDA Approval Status
FDA Approved: No
Brand name: Extravan
Generic name: travoprost and timolol
Dosage form: Ophthalmic Solution
Company: Alcon Laboratories, Inc.
Treatment for: Glaucoma
Extravan (Travoprost 0.004% + Timolol 0.5% Fixed Combination (TTFC)) is a prostaglandin analogue and beta-blocker combination intended for use in the treatment of glaucoma.
In September 2004, Alcon, Inc. announced the receipt of an Approvable Letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for Extravan. While the combination is currently available in many countries, it remains commerically undeveloped in the United States.
Development timeline for Extravan
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
